The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)
Open accessAbstract
Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH). In the 16-week CHEST-1 study, riociguat showed a favourable benefit–risk profile and improved several clinically relevant end-points in patients with CTEPH. The CHEST-2 open-label extension evaluated the long-term safety and efficacy of riociguat. Eligible patients from CHEST-1 received riociguat individually adjusted up to a maximum dose of 2.5 mg three times daily. The primary objective was the safety and tolerability of riociguat; exploratory efficacy end-points included 6-min walking distance (6MWD) and World Health Organization (WHO) functional class (FC). Overall, 237 patients entered CHEST-2 and 211 (89%) were ongoing at this interim analysis (March 2013). The safety profile of riociguat in CHEST-2 was similar to CHEST-1, with no new safety signals. Improvements in 6MWD and WHO FC observed in CHEST-1 persisted for up to 1 year in CHEST-2. In the observed population at 1 year, mean±sd 6MWD had changed by +51±62 m (n=172)versus CHEST-1 baseline (n=237), and WHO FC had improved/stabilised/worsened in 47/50/3% of patients (n=176)versus CHEST-1 baseline (n=236). Long-term riociguat had a favourable benefit–risk profile and apparently showed sustained benefits in exercise and functional capacity for up to 1 year.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Self-citationUpdated Clinical Classification of Pulmonary Hypertension
Simonneau, G., Robbins, I. M., Beghetti, M., Channick, R. N., Delcroix, M., Denton, C. P., Elliott, C. G., Gaine, S. P., Gladwin, M. T., Jing, Z.-C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.012 · Cited by 2,093
Self-citationRiociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Ghofrani, H.-A., D'Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,401
Self-citationRiociguat for the treatment of pulmonary arterial hypertension
Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209655 · Cited by 1,346
Self-citationChronic Thromboembolic Pulmonary Hypertension
Hoeper, M. M., Mayer, E., Simonneau, G., & Rubin, L. J. (2006) · Circulation · doi:10.1161/circulationaha.105.602565 · Cited by 1,148
Self-citationMayer, E., Jenkins, D., Lindner, J., D’Armini, A., Kloek, J., Meyns, B., Ilkjaer, L. B., Klepetko, W., Delcroix, M., Lang, I., et al. (2011) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2010.11.024 · Cited by 733
Self-citationUpdated Treatment Algorithm of Pulmonary Arterial Hypertension
Galiè, N., Corris, P. A., Frost, A., Girgis, R. E., Granton, J., Jing, Z. C., Klepetko, W., McGoon, M. D., McLaughlin, V. V., Preston, I. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.031 · Cited by 667
Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Chronic Thromboembolic Pulmonary Hypertension
Kim, N. H., Delcroix, M., Jenkins, D. P., Channick, R., Dartevelle, P., Jansa, P., Lang, I., Madani, M. M., Ogino, H., Pengo, V., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.024 · Cited by 519
Self-citationWilkens, H., Konstantinides, S., Lang, I. M., Bunck, A. C., Gerges, M., Gerhardt, F., Grgic, A., Grohé, C., Guth, S., Held, M., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.08.079 · Cited by 219
Self-citation
Cited by
The pathophysiology of chronic thromboembolic pulmonary hypertension
Simonneau, G., Torbicki, A., Dorfmüller, P., & Kim, N. (2017) · European Respiratory Review · doi:10.1183/16000617.0112-2016 · Cited by 461
Self-citationChronic Thromboembolic Pulmonary Hypertension
Piazza, G., & Goldhaber, S. Z. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0910203 · Cited by 410
Chronic thromboembolic pulmonary hypertension
Hoeper, M. M., Madani, M. M., Nakanishi, N., Meyer, B., Cebotari, S., & Rubin, L. J. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70089-x · Cited by 272
Self-citation
Metadata
- Authors
- Simonneau, G., D’Armini, A. M., Ghofrani, H.-A., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Wang, C., Wilkins, M. R., Fritsch, A., Davie, N., Colorado, P., & Mayer, E.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2014-11-13
- Volume
- 45
- Issue
- 5
- Pages
- 1293-1302
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2108559440
- Cited by
- 315
- References
- 23
- FWCI
- 23.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). https://app.cochat.ai/papers/10.1183/09031936.00087114
- The paper
- Simonneau, G., D’Armini, A. M., Ghofrani, H.-A., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Wang, C., Wilkins, M. R., Fritsch, A., Davie, N., Colorado, P., & Mayer, E. (2015). Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). European Respiratory Journal. https://doi.org/10.1183/09031936.00087114
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.